Overview

Description

  • Nature
    Recombinant
  • Source
    HEK 293 cells
  • Amino Acid Sequence
    • Accession
    • Species
      Human
    • Sequence
      ALDTNYCFSS TEKNCCVRQL YIDFRKDLGW KWIHEPKGYH ANFCLGPCPY IWSLDTQYSK VLALYNQHNP GASAAPCCVP QALEPLPIVY YVGRKPKVEQ LSNMIVRSCK CS
    • Molecular weight
      25 kDa
    • Amino acids
      279 to 390
    • Additional sequence information
      TGF-beta1 is a 25.0 kDa protein with each subunit containing 112 aa, linked by a single disulfide bond. It is the mature protein after cleavage of the signal peptide and latency-associated peptide.

Associated products

Specifications

Our Abpromise guarantee covers the use of ab50036 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity

    The ED50 was determined by TGF-beta1's ability to inhibit the mouse IL-4-dependent proliferation of mouse HT-2 cells is ≤ 0.05 ng/ml, corresponding to a specific activity of ≥ 2 x 107 units/mg.

  • Applications

    SDS-PAGE

    Functional Studies

    Western blot

  • Purity
    > 95 % SDS-PAGE.
    Greater than 98% by SDS-PAGE and HPLC analyses.
  • Form
    Lyophilised
  • Additional notes

    TGF-beta is secreted predominantly as latent complexes which are stored at the cell surface and in the extracellular matrix. The release of biologically active TGF-β isoform from a latent complex involves proteolytic processing of the complex and /or induction of conformational changes by proteins such as thrombospondin-1. TGF-β1 is the most abundant isoform secreted by almost every cell type.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: None
    Endotoxin level is less than 0.1 ng per µg (1EU/µg).

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

  • Reconstitution
    Centrifuge the vial prior to opening. Reconstitute in 10mM Citric Acid, pH3.0 to a concentration of 50 µg/ml (e.g. 5 µg/100µl). This solution can then be stored at room temperature or at 4oC for 1 month. It is recommended that further dilutions be made in PBS containing 2 mg/ml albumin and stored at -20oC for future use.

General Info

  • Alternative names
    • Cartilage-inducing factor
    • CED
    • Differentiation inhibiting factor
    • DPD1
    • LAP
    • Latency-associated peptide
    • Prepro transforming growth factor beta 1
    • TGF beta
    • TGF beta 1
    • TGF beta 1 protein
    • TGF-beta 1 protein
    • TGF-beta-1
    • TGF-beta-5
    • TGF-beta1
    • TGFB
    • Tgfb-1
    • tgfb1
    • TGFB1_HUMAN
    • TGFbeta
    • TGFbeta1
    • Transforming Growth Factor b1
    • Transforming Growth Factor beta 1
    • Transforming growth factor beta 1a
    • transforming growth factor beta-1
    • transforming growth factor, beta 1
    • Transforming Growth Factor-ß1
    see all
  • Function
    Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
  • Tissue specificity
    Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
  • Involvement in disease
    Defects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
  • Sequence similarities
    Belongs to the TGF-beta family.
  • Post-translational
    modifications
    Glycosylated.
    The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
  • Cellular localization
    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt

References

This product has been referenced in:
  • Chanda S  et al. Rotavirus-induced miR-142-5p elicits proviral milieu by targeting non-canonical transforming growth factor beta signalling and apoptosis in cells. Cell Microbiol 18:733-47 (2016). Read more (PubMed: 26572508) »
  • Salis O  et al. Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes. Tumour Biol 37:3017-24 (2016). Read more (PubMed: 26419593) »
See all 10 Publications for this product

Customer reviews and Q&As

1-10 of 19 Abreviews or Q&A

Answer

Thank you for your enquiry.

I have reviewed with our sources the TGF beta 1 proteins that we have on our catalog. It seems the most suitable would be ab50036 TGF beta 1 protein (Active).

https://www.abcam.com/index.html?datasheet=50036 (or use the following: https://www.abcam.com/index.html?datasheet=50036).

This should be suitable for use on human cells, as it is a human protein. Unfortunately, I am sorry we do not have any information if it has been used specifically for in the in vitro induction of EMT in human cell lines, but there are many references on our website for this product which state usage of this product in a variety of applications.

https://www.abcam.com/TGF-beta-1-protein-Active-ab50036-references.html

I hope this will be helpful to you. If you have any further questions, please do not hesitate to contact us.

Read More

Answer

HCl can be used as an alternative at the same recommended molarity and pH (10 mM, pH 3).

Read More

Answer

It is important to strictly follow the reconstitution protocol on the datasheet. Reconstituting our TGF-β1 in acetic acid instead of the recommended citric acid will not fully dissolve this product in solution which may adversely affect its performance in an assay.

Read More

Question
Answer

Thank you for contacting us. Reconstitution instructions for the proteins are below.

Centrifuge the vial prior to opening. Reconstitute in 10mM Citric Acid, pH 3.0 to a
concentration of 0.1-1.0 mg/ml. Do not vortex. For
extended storage, it is recommended to further dilute in a
buffer containing a carrier protein (example 0.1% BSA) and
store in working aliquots at -20oC to -80oC.

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

Answer


Reconstitution of ab50036 should be performed as indicated on the datasheet:
1. Centrifuge the vial prior to opening.
2. Reconstitute in 10mM Citric Acid, pH 3.0 to a concentration of 0.1-1.0 mg/ml. Do not vortex.
3. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20oC to -80oC.
These conditions are optimized to ensure complete solubility and required bioactivity of Human TGF-β1. I would advise to strictly follow the protocol to avoid loss of activity.

Below is an article published in 2009 where the authors used a Human TGF-β1 in vivo. Reviewing this article may be helpful for further information.
Freeman, I The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials;30(11):2122-31. 17 Jan 2009. PMID 19152972.

Read More

Answer


ab51967 is delivered in 10ug. First, make the 1ug/ul solution by diluting the 10ug in 10ul of water. Then, take 1ul of that solution and dilute it in 99ul of water to make the 0.01 ug/ul solution.
ab50036 is delivered in 5ug. First, make the 1ug/ul solution by diluting the 5ug in 5ul of 10mM Citric Acid, ph3.0. Then, take 1ul of that solution and dilute it in 99ul of 10mM Citric Acid, ph3.0 to make the 0.01 ug/ul solution. For longer term storage at -20oC of the 0.01 ug/ul solution, 99ul of PBS containing 2 mg/ml albumin can be used instead of 99ul of 10mM Citric Acid.

Read More

Answer

Thank you for contacting us and for your patience.

I had to contact the laboratory in order to get more information about the use of these three proteins.

I can confirm, that for the ab92965 SPARC protein (MBP) to our knowledge it has not been tested for injection in mice or other animals (besides it uses as immunogen for polyclonal antibodies production in rabbits intramuscular). It could be that it will work for injection in mice but we can not guarantee this and we have no information about different administration routes (intravenous, intramuscular etc.).

The two other proteins have been used in mice before. See the following links:

1. ab9571 VEGF protein (Active)

http://www.ncbi.nlm.nih.gov/pubmed/19088027

http://www.ncbi.nlm.nih.gov/pubmed/10784613

http://www.ncbi.nlm.nih.gov/pubmed/11689883

http://www.ncbi.nlm.nih.gov/pubmed/12036930

http://www.ncbi.nlm.nih.gov/pubmed/9401980

http://www.ncbi.nlm.nih.gov/pubmed/15358628

http://www.ncbi.nlm.nih.gov/pubmed/16477043

http://www.ncbi.nlm.nih.gov/pubmed/16888632

http://www.pnas.org/content/104/8/2837.full

http://www.ncbi.nlm.nih.gov/pubmed/18180379

http://www.ncbi.nlm.nih.gov/pubmed/15067321

http://www.ncbi.nlm.nih.gov/pubmed/20056792

http://www.ncbi.nlm.nih.gov/pubmed/22025303

http://www.pnas.org/content/early/2011/07/25/1016546108.abstract



2. ab50036 TGF beta 1 protein (Active)

http://www.ncbi.nlm.nih.gov/pubmed/20304823

http://www.ncbi.nlm.nih.gov/pubmed/22761317

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

Answer

Thank you for contacting us.


I like to reassure that if there was no protein in the vial that will be covered by our guarantee and we will be pleased to provide a credit note, free of charge replacement or refund if that is this case.

I can confirm that 5 ug is a very small amount. It can not necessarily be seen even after centrifugation.


Could you kindly provide the result of the earlier discussed SDS-PAGE? The result should confirm rather there is some protein in the vial or not.

I hope this information is helpful to you and looking forward to receive the requested information.


Use our products? Submit an Abreview. Earn rewards!
https://www.abcam.com/abreviews

Read More

Question
Answer

Thank you for contacting us. This TGF beta 1 protein (ab50036) has been sterile filtered through a 0.2 micron filter prior to lyophilization and it would therefore not be necessary to sterilize it again. Filtration with a 0.2 micron filter will not have any effect on the activity, however. I hope this helps, please let me know if you need any additional information or assistance.

Read More

Answer

Thank you for contacting us.

The TGF beta 1 protein ab50036 is supplied carrier-free and was lyophilized from a solution containing 0.1% trifluoroacetic acid.

For reconstitution, the recommendation for this lot is:

Centrifuge the vial prior to opening. Reconstitute in 10mM Citric Acid, pH 3.0 to a concentration of 0.1-1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20oC to -80oC.

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

1-10 of 19 Abreviews or Q&A

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up